
...BIBLIOGRAPHY...

- A pneumococcal conjugate vaccine for infants and children. *Med Lett Drugs Ther* 2000;42:25-28.
- Anttilla M, Eskola J, Ahrnan H, Kayhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. *Vaccine* 1999;17:1970-1977.
- Berman S. Otitis media in children. *N Engl J Med* 1995;332:1560-1565.
- Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. *Pediatr Infect Dis J* 2000;19:187-195.
- Black S, Shinefield H. Progress toward effective pneumococcal vaccination in infancy. *Contemp Pediatr* 1998;Nov(Suppl):2-17.
- Bluestone CD, Klein JO. Otitis Media in Infants and Children, 2nd ed. Philadelphia, PA: WB Saunders; 1995.
- Bureau of Labor Statistics. Consumer Price Index (CPI), Medical care services. Available at: <http://146.142.4.24/cgi-bin/surveymost>. Accessed March 2, 2000.
- Centers for Disease Control and Prevention. Ambulatory and inpatient procedures in the United States, 1996. Series 13. Data from the National Health Care Survey, No. 139, PHS 99-1710; November 1998.
- Centers for Disease Control and Prevention. CDC Vaccine Price List. Available at: <http://www.cdc.gov/nip/vfc/pricelist.pdf>. Accessed April 25, 2000.
- Centers for Disease Control and Prevention. Drug resistant *Streptococcus pneumoniae*: Kentucky and Tennessee, 1993. *MMWR Morb Mortal Wkly Rep* 1994;43:28-35.
- Centers for Disease Control and Prevention. Prevention of pneumococcal disease: Recommendations of the advisory committee on immunization practices (ACIP). *MMWR Morb Mortal Wkly Rep* 1997;46(RR-08):1-24.
- Centers for Disease Control and Prevention. Progress toward elimination of *Haemophilus influenzae* type b among infants and children: United States, 1987-1993. *MMWR Morb Mortal Wkly Rep* 1994;43:144-148.
- Cochi SL, Broome CV, Hightower AW. Immunization of U.S. children with *Haemophilus influenzae* type b polysaccharide vaccine. *JAMA* 1985;253:521-529.
- Dagan R, Melamed R, Muallem M, et al. Reduction of a nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. *J Infect Dis* 1996;174:1271-1278.
- Dagan R, Muallem M, Leroy O, Yagupsky P. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. *Pediatr Infect Dis J* 1997;16:1060-1064.
- Eisenberg JM. Clinical economics: A guide to the economic analysis of clinical practices. *JAMA* 1989;262:2879-2886.
- Eskola J. Efficacy of pneumococcal conjugate vaccine against otitis media (Late-Breaker Abstract). Presented at the 39th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 26 to 29, 1999.
- Fleming TR, Harrington DP. Counting processes and survival analysis. New York, NY: Wiley; 1991.
- Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant *Streptococcus pneumoniae*. *N Engl J Med* 1994;331:337-342.
- Froom J, Culpepper L, Grab P, et al. Diagnosis and antibiotic treatment of acute otitis media: Report from International Primary Care Network. *Br Med J* 1990;300:582-586.
- Health Resources and Services Administration. (1999). National Vaccine Injury Compensation Program. Available at: <http://www.hrsa.dhhs.gov/bhpr/vicp/sum-cur.htm>. Accessed April 11, 2000.
- Hueston WJ, Mainous AG, Brauer N. Predicting cost-benefits before programs are started: Looking at conjugate vaccine for invasive pneumococcal infections. *J Community Health* 2000;25:23-33.
- Huse DM, Meissner HC, Lacey MJ, Oster G. Childhood vaccination against chickenpox: An analysis of benefits and costs. *J Pediatr* 1994;124:869-874.
- Koplan JP, Preblud SR. A benefit-cost analysis of mumps vaccine. *Am J Dis Child* 1982;136:362-364.
- Koplan JP, Schoenbaum SC, Weinstein MC, Fraser DW. Pertussis vaccine: An analysis of benefits, risks and costs. *N Engl J Med* 1979;301:906-911.
- Krahn M, Guasparini R, Sherman M, Detsky AS. Costs and cost-effectiveness of a universal, school-based hepatitis b vaccination program. *Am J Public Health* 1998;88:1638-1644.
- Lieu TA, Cochi SL, Black SB, et al. Cost-effectiveness of a routine varicella vaccination program for US children. *JAMA* 1994;271:375-381.

...BIBLIOGRAPHY...

- Lieu TA, Ray GT, Black SB, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. *JAMA* 2000; 283:1460-1468.
- Margolis HS, Coleman PJ, Brown RE, Mast EE, Sheingold SH, Arevalo JA. Prevention of hepatitis b virus transmission by immunization. *JAMA* 1995;274: 1201-1208.
- National Center for Health Statistics. *Vital Statistics of the United States, 1992, Vol II, Mortality*, Part B. Washington, DC: Public Health Service;1996.
- Palton FI. Otopscopy for the diagnosis of otitis media. *Pediatr Infect Dis J* 1998;17:540-543.
- Pneumococcal vaccine. *Med Lett Drugs Ther* 1999; 41:84.
- Quataert SA, Kirch CS, Wiedl LJ, et al. Assignment of weight-based antibody units to a human anti-pneumococcal standard reference serum lot 89-S. *Clin Diag Lab Immunol* 1995;2:590-597.
- Rannels MB, Edwards KM, Kayserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. *Pediatrics* 1998;101:604-611.
- Rubin LG, Mardy GV, Pais L, Carlone G. Human anti-capsular antibody concentration required for protection against experimental pneumococcal bacteremia (Abstract G-47). In: Proceedings of the 35th Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17 to 20, 1995. Washington, DC: American Society for Microbiology, 1995.
- Saladino RA, Stack AM, Malley R, Thompson CM, Siver CR, Fleiser GO. Bacterial polysaccharide immune globulin (BPIG) protects infant rats with *S. pneumoniae* (SP) pneumonia from bacteremia, meningitis and death. *Pediatr Res* 1996;36:184A.
- SAS Institute Inc. SAS/STAT Software: Changes and enhancements through release 6,12. Cary, NC: SAS Institute Inc.; 1997:942.
- Schappert SM. Office visits for otitis media: United States, 1975-90. *CDC Advance Data* 1992;214:1-20.
- Schappert SM. *Office Visits for Otitis Media: United States, 1975-1990. Advance Data from Vital and Health Statistics*. Hyattsville, MD: National Center for Health Statistics; 1992. Publication 214.
- Scheifele DW, Halperin SA, Guasparini R, Meekison W, Pim C, Barreto L. Extended follow-up of antibody levels and antigen responsiveness after 2 *Haemophilus influenzae* type b conjugate vaccines. *J Pediatr* 1999;135:240-245.
- Schoenbaum SC, Hyde JN, Bartoshesky L, Crampton R. Benefit-cost analysis of rubella vaccination policy. *N Engl J Med* 1976;294:306-10.
- Shann F. Pneumococcus and influenza. *Lancet* 1990;335:898-901.
- Shinefield HR, Black S, Ray P, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. *Pediatr Infect Dis J* 1999;18:757-763.
- Shurin PA, Rehmus JM, Johnson CE, et al. Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high risk children. *J Pediatr* 1993;123:801-810.
- Siber GR. Methods for estimating serologic correlates of protection. *Dev Biol Stand* 1997;89:283-296.
- STAT EXACT Statistical Package. Cambridge, MA: Cytel Statistical Software; 1998.
- Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. *JAMA* 1996;276:1253-1258.
- Zenni MK, Cheatham SH, Thompson JM, et al. *Streptococcus pneumoniae* colonization in the young child: Association with otitis media and resistance to penicillin. *J Pediatr* 1995;127:533-537.

...NOTES...